YOUNG, E A., J. M WALKER, R HOUGHTEN AND H AKIL. The degradatton ofdynorphm A m bram tt~sue m vlvo and m vitro. PEPTIDES 8(4) [701][702][703][704][705][706][707] 1987.--The demonstration of analgesia following m vtvo admlmstratlon of dynorphln A (Dyn A) has been difficult In contrast, a number of electrophyslologlcal and behaworal effects reported with m vtvo rejection of Dyn A can be produced by des-tyrosme dynorphm A (Dyn A 2-17). This suggested the extremely rapid amino terminal degradation of dynorphm A To test this hypothesis, we examined the degradation of dynorphm A following m vtvo rejection into the penaqueductal gray (PAG) as well as m vttro using rat brain membranes under receptor binding conditions. In vtvo, we observed the rapid amino terminal cleavage of tyrosme to yield the relatively more stable destyrosme dynorphm A This same cleavage after tyrosme was observed tn vttro. Inhibition of this amlnopeptldase actlwty tn vttro was observed by the ad&tlon of dynorphln A 2-17 or dynorphm A 7-17 but not after the addition of dynorphm A 1-13, dynorphm A 1-8, dynorphln B or a-neo-endorphm suggesting a specific enzyme may be responsible The detection of the behaviorally active des-tyrosme dynorphm A following m vtvo rejection ofdynorphm A suggests that this peptlde may play an important physiological role.
Dynorphm A

In vtvo In vttro
Penaqueductal gray DYNORPHIN A has been shown to be an extremely potent opiold peptlde active at several opioid receptors in a number of m vitro preparations [4, 11, 16--19, 29, 43] . Despite the demonstratton of its high affinity binding to brain membrane receptors, and its substantml potency m guinea p~g deum preparations, demonstration of analgesia following m vlvo rejection has been difficult [13-15, 19, 27, 28, 38, 42] . A number of behavlorial and electrophysiological effects have been reported followmg in vivo injection of pharmacological doses ofdynorphm A [1, 2, 10, 19, 25, 27, 28, 35, 36, 38, 42] . With the exception of diuresis, the behavioral and physiological effects often appear to be non-oploid since they cannot be reversed by high doses of naloxone (10 mg/kg) or other opiate antagonists, and, these same effects can be produced by dynorphin A 2-13 or dynorphin A 2-17 [10, 28, 40, 42] . One explanation for the lack of potency of dynorphin A in tests of thermal pain stems from findings that kappa agonlsts are weak in tests of thermal pain [23] . However, the kappa opiold U-50488H was found to be active m the tail flick test after either systemic or intracerebroventncular injections m rats [37] . Early stu&es with another opioid peptide, enkephahn, showed slmdar difficulties demonstrating analgesia after m vtvo injection of pharmacological doses [3, 9] . In the case of enkephalin, these difficulties resulted from extremely rapid breakdown of enkephalin following in vtvo injection [9, 12, 21, 22, 24, 33, 34] . The availability of stable analogues of enkephalin led to the demonstration of a variety of opioid effects with these compounds [6, 7, 26, 39, 41] . However, in the case of dynorphin A, the stable analogues produced thus far have altered the receptor selectwlty of dynorphin A, and thus changed the pharmacological profile of dynorphin A [5] . Smce suitable stable analogues are not available, it xs criUcal to examine the stability of dynorphm A following in vtvo injection and see if we could detect any fragments of dynorphin A that are known to be behaviorally active such as dynorphin A 2-17 or dynorphin A 1-8.
Aside from concerns about the stability of dynorphin A following m vlvo injecUons, studies on the degradation of brain peptides and other neurotransmitters can yield important information. In the enkephahn system, despite the widespread presence of general amlnopeptidases that could use enkephalin as a substrate, in vtvo degradation stu&es demonstrated that a family of enzymes, the enkephalinases, were responsible for the in vivo breakdown [9, 12, 21, 22, 24, 33, 34] . The existence of such specific degrading enzymes provides another regulatory stte in neurotransmitter systems. Inhibitors of such specific enzymes can provide other strategies for studying neuronal regulation or for prolonging the actions of endogenous llgands released under physiological conditions ( [31] and cf. monoamine oxidase mhlbitors).
In addition to concerns about in vlvo breakdown of dynorphin A, breakdown of dynorphm A in in vitro systems can alter its pharmacological profile. During our own recep-tor binding studies, we became concerned about the rapid breakdown of this endogenous peptide in our membrane preparation. Since opioid binding activity is dependent upon an intact tyroslne at the N-terminal, it is particularly cntical to assure that the peptlde is stable under these conditions. Similar studies with CCK-33 binding have demonstrated breakdown under binding conditions that can be inhibited by bacltracln, yielding a 2-fold increase in specific binding [32] . Previous studies by Leslie and Goldsteln [20] in rat brain membrane preparations using [~25I] dynorphln A 1-13 had demonstrated extremely rapid NH~-termlnal cleavage of the tyrosine as well as rapid progressive COOH-termlnal shortening. Similarly, m vttro rat membrane data by Robson et al. [30] using dynorphln A 1-9 demonstrated that nonspeclfiC inhibition of the NH.,-terminal cleavage of tyroslne led to COOH-terminal shortening and formation of numerous other opioid-actlve dynorphln fragments, making true pharmacologic characterization of dynorphln A impossible under these conditions Interestingly, the data from Leslie and Goldsteln [20] suggested the existence of a specific membrane bound exopeptidase in rat brain that could be inhibited by COOH-terminal fragments of dynorphin A 1-13 (dynorphin A 6-13), but only in concentrations that affected oplold binding. To explore these problems, we undertook 
METHOD
Tl~ue Preparatton
Rat and guinea pig brains minus the cerebellum were homogenized with a Brinkman polytron in 50 mM Tris buffer (pH 7.4 at 24°C) at a concentration of 50 mg tissue (wet weight) per ml of buffer. After a 40 minute 37°C incubation to dissociate bound ligands, the homogenates were centrifuged at 40,000 × g, then resuspended m 50 mM Tris at a concentration of 37.5 mg tlssue/ml.
Product Identification
The ['~H]dynorphm A used for all these studies was synthesized by one of us (R.H. Two methods of chromatography were employed, a rapid molecular seiving with a short Sephadex column, followed by more complete identification with reverse phase HPLC. The supernatant was applied to a 12 centimeter G-10 column equilibrated in 2 N acetic acid with 0.1W/o BSA for molecular sieving. Using MeOH:HCI as an eluant, fractions (0.5 ml) were collected directly into scintillation vials.
[3H]dynorphin A, [3H]Leu-enkephalin and [3H]tyroslne were used as standards This column reliably separates dynorphin A from dynorphln A 1-8 from Leu-enkephahn. However, it does not separate Leu-enkephahn from tyrosine. Dynorphln A 1-13 co-migrates with dynorphln A on this column. The fractions were suspended in l0 ml of scintillation cocktail for aqueous samples and counted in a Beckman LS 9000 scintillation counter. The bound (tissue pellet) was also counted to calculate recovery of [3H]dynorphln A as well as to determine both specific and nonspeclfiC tissue binding by centrifugatlon. Dynorphln A (Dyn A), dynorphln A 2-17 (dT dynorphln) and dynorphln A 7-17 were a generous gift of Dr. David Coy. Dynorphln A 1-8 and dynorphln A 1-13 were purchased from Peninsula (Belmont, CA) and c~-neo-endorphln was purchased from Bachem (Torrance, CA).
For final identification of products, separation by reverse phase HPLC was undertaken. Buffer A consisted of 0.1% trlfluoroacetlc acid (TFA) in water with 0.05% trlethylamlne (TEA). Buffer B consisted of 0.1% TFA, 80c~ acetonltrlle, 19.9% water with 0 05°~ TEA. Beginning at 4% Buffer A, a 10-minute gradient rising to 12% B produced separation of Tyr, Tyr-Gly and Tyr-Gly-Gly fragments A 5-minute gradient from 12% to 27% B was followed by a 45-minute gradient between 27-38c~ buffer B which produced good separation of Leu-enkephahn, dynorphln A 1-8 and dynorphln A For use in these breakdown experiments, the ['~H]dynorphin A was repurlfied on the HPLC so all radioactivity co-migrated w~th the dynorphin A standard This repurlfied [~H]dynorphln A was tested for opiate bindIng activity to further insure that it was ['~H]dynorphln A After 0, 15, 30, 60 and 90 minutes incubation of 1 nM ['~H]dynorphln A with brain homogenates, the supernatant was lyophlhzed, resuspended in MeOH HCI and then applied to the HPLC for separation. To insure proper Identification of dynorphln and dynorphin fragments, unlabelled peptide fragments and tyroslne were added as standards in each HPLC sample run, and the fractions were counted with a Beckman LS 9000 Scintillation Counter to determine whether radioactivity co-migrated with dynorphln A or other dynorphln fragments as monitored by UV (220 nm). Recovery was monitored by quantltlfylng the radioactivity applied to column and the counts recovered For those studies In which dynorphln fragments were measured by radloimmunoassay, dynorphln A, dT dynorphln and dynorphln A 1-8 were not added. To assess the elutlon profile of those standards, a calibration HPLC run followed the sample runs on each day
In Vlvo Studtes
For m vtvo studies, 25 ga stainless steel guide cannulae were implanted Into the perlaqueductal gray (PAG) using the coordinates 5 1 mm posterior to bregma, 0.5 mm lateral to midhne, with the guide cannulae inserted to a depth of 4.5 mm (Nose + 0.5 mm tilt) (Pellegrlno, Pellegrlno and Cushman, 1971). Seven to 10 days following surgery, the animals received an injection of 0.1 nanomole of [3H]dynorphln A plus 0.9 nanomole of unlabelled dynorphln A through a 30 ga stainless steel needle extending 2 mm beyond the guide into the PAG. The Injection volume was 1 mlcroliter administered over 1 minute. To minimize backflow, the needle remained in place for 30 seconds after the end of the rejection. After varying time periods (0, 2.5, 5 and 10 minutes), the rats were decapitated, their brains rapidly removed, and using a stereotactic block, a 2 mm slice of the PAG and the area 2 mm immediately rostral to the PAG were dissected The cortex and collicuh were trimmed Data are expressed as percent of total rad~oactwlty recovered from these regmns and then these regions were immediately homogenized in extraction buffer (3:1 acetone:0.2 N HCI). The time from decapitation to homogenization averaged 1.5 minutes. After centrifugation, the supernatant was lyophlhzed, then resuspended in MeOH:HC1 for the HPLC separation and identification. The radioactivity recovered in the tissue averaged 10% of the infused counts. It is unclear if the low recovery m tissue occurred because of nonspeclfiC loss to the cannula or guide or because of diffusion of radioactivity from the site of injection. However, when we extracted the areas surrounding the dissected regions httle radioactivity was found. More than 95~ of the radloactiwty m the t~ssue was present in the supernatant after extraction. The extracted material was applied to HPLC in MeOH:HC[ and separated using the gradient described above.
After HPLC, half of each fraction was counted for radioactivity. The total radioactivity recovered from the HPLC runs averaged 91)% of the material applied to the column. To characterize the forms of dynorphin immunoreactwlty present after m v~vo rejection, the other half of each fraction was radioimmunoassayed with a dynorphm A antibody raised m our laboratory to dynorphin A 1-17 [8] . This antibody is fully cross reactive with dynorphin A 2-17, but does not recognize dynorphm A 1-8 and is only 51)% cross reactive with dynorphln A 1-13.
RESULTS
In Vitro Results
Time course studies using single washed membranes with HPLC identification and quantitation demonstrated rapid degradation of dynorphin A following m vitro incubation wnh brain homogenates. At the end of 60 minutes incubaUon only 23% of the dynorphm A is intact. In contrast, double washed membranes showed slower breakdown (Fig. 1) . The HPLC separation ~dentified the major radioactive breakdown fragment as [3H]tyrosme. The rest of radioactivity co-migrated w~th dynorphin A or Leu-enkephalin.
Initial inhibitor studies were done following 90 minutes incubation at 0°C, the optimal time for [3H]dynorphin A binding m brain homogenates. Table 1 shows the data from one experiment. Molecular sieving with G-10 columns was used to quantitate breakdown and inhibition by other peptides. Thus, after 90 minutes incubation at 0°C with rat membranes, only 23% of the radioactivity co-migrates with [3H]dynorphln A size material, while 67% of the radioactivity is [ZH]tyrosine size. In contrast, in guinea pig brain homogehates at 0°C, 40% of the radioactivity elutes with the [3H]dynorphm A standard, while only 50% of the radioactivity is [3H]tyroslne size material. In both species, the addition of 1 mlcromolar unlabelled dynorphm A substantially inhibits the breakdown of the [3Hldynorphln A. It should be noted, however, that even this high concentration of unla- To calculate % inhibition the following formula was 100 -% Dyn A intact with inhibitor 100 belled dynorphm A does not totally prevent the breakdown of the [aH]dynorphin A in either species• Using the same molecular sieving quantltatlon, destyrosme dynorphln A (dT-Dyn or dynorphln A 2-17) appears to inhibit the breakdown of [aH]dynorphin A to the same extent as dynorphln A in rat brain. This is not the case in guinea pig brain, where dynorphin A is more effective at preventing breakdown of [aH]dynorphln A than is dT dynorphin Thus, there appear to be species differences in the ammopeptidases that cleave the NH2-terminal tyroslne from dynorphm A. The ability of dynorphln 2-17 to block the breakdown may represent classic end-product inhibition through an allosteric site, or, alternatively, it may be that the recogmtlon site for this dynorphin ammopeptldase is dependent upon the non-opiate core of dynorphln. Consequently we explored the effects of other dynorphin related pepttdes on the breakdown of [aH]dynorphm A in rat brain (Table 2) . Since we wanted to minimize the breakdown of the competing peptides, we used a shorter incubation time of 60 minutes at 0°C.
Again using molecular sieving quantltatlon, it can be seen in Table 2 that the non-opiate containing sequence of dynorphm A, dynorphin A 7-17, is able to partially inhibit the breakdown of [3H]dynorphIn A. It is not as effective an inhibitor as dynorphin A of dT dynorphln, but tt posesses approximately 50% of the activity of dynorphin A itself. When the concentration is increased to 10/xM, dynorphin A 7-17 shows similar inhibition as 1/xM dynorphin A. Dynorphln A 1-13, dynorphin B and a-neo-endorphIn show some small inhibitory actions at 10/xM concentration. Met-enkephalln 2-5, a classic enkephalinase inhibitor, does not affect the breakdown (data not shown), nor does dynorphin A 1-8, another prodynorphln derived peptide. If a specific enzyme exists, the failure to demonstrate inhibition by dynorphin A 1-8 may indicate either a lack of recognition of this peptide or that dynorphin A 1-8 is broken down so rapidly that by 60 minutes there is no longer any "inhibitor" left. Thus, similar studies were undertaken at 30 minutes. Even after 30 minutes incubation at 0°C, dynorphin A 1-8 showed no inhibition of the amino terminal cleavage of tyrosine from dynorphin A, when compared to the [3H]dynorphin A breakdown standard for that experiment.
In Vivo Re,suits
Using HPLC, m vtvo breakdown was quantltated and (Figs. 2 and 3) . Thus, even ume 0 samples show less than 50% of the radioactivity co-migrating with dynorphin A on HPLC. The rest of the radsoactwity co-migrates with tyrosme. This aminotermmal cleavage of tyrosme appears to be common to both m vitro and in vtvo preparations. Since dT dynorphin has been shown to be biologically active, ~t was of interest to see if dT dynorphm was formed and stable following the loss of tyrosine from dynorphin. The results are m Fig. 4 . Substantial dT dynorphm can be demonstrated by radioimmunoassay. In the area of injection (PAG) at the end of 10 minutes, our longest time point, 84% of the dynorphin A-IR co-migrates wlth dT dynorphin. The total of dT dynorphin-IR plus dynorphin A-IR equaled the amount rejected, suggesting that there is little loss of dynorphin A by conversion of dT dynorphin to other fragments that were not recognized by our antibody. The ratio of [aH]dynorphm A to [~H]tyroslne (80%:20%) is the same as the ratio of dynorphm A to dT dynorphin (84%:16%) in these same fractions. This suggests that injection of dynorphin A is followed by rapid ammo terminal cleavage with the formation of a relatively more stable compound, dT dynorphm. However, without a time course of dT dynorphin breakdown it is not possible to conclusively demonstrate the stabihty of dT dynorphin m vivo. But, at the 10 minute time point 5-6-fold more dT dynorphin then dynorphin A is present.
DISCUSSION
The difficulty in demonstrating [aH]dynorphm A binding to rat brain membranes suggested that the breakdown of [3H]dynorphln A was extremely rapid. Leslie and Goldstem had published similar findings with [lzsI]dynorphin A 1-13 [20] . Our time course studies in vitro confirm this notion. In single washed membranes, the breakdown proceeded very rapidly even at 0°C, resulting in less than 25% of the material intact at 30 minutes. In contrast, using double washed membranes substantially slowed the breakdown of [3H]dynorphin A in vitro Therefore, the proteolytic enzymes may be loosely associated with the membranes, suggesting nonspecific soluble enzymes may be involved in breakdown in vLtro. In all cases, the radiolabelled breakdown product appeared to be [3H]tyrosIne, without evidence of cleavage at the other sites such as between Gly-Gly or Gly-Phe to yield Tyr-Gly or Tyr-Gly-Gly. This suggests that enkephalinases are not the primary enzymes involved in the breakdown under these conditions. In the double washed membrane preparation, the continued co-migration on HPLC of [aH]dynorphin A with the unlabelled standard suggests that extensive carboxy terminal cleavage is not occurring under these conditions. This is in contrast to the data of Leslie and Goldstein for dynorphin A 1-13 [20] and Robson et al. [31] for dynorphin A 1-9, who found that carboxy terminal cleavage proceeds at a rate similar to amino terminal cleavage. It may be that the native full structure (Dyn A) 1s more resistant to carboxy-peptidase activity. Likewise, we were unable to demonstrate by HPLC any [3H]dynorphin A 1-8 size peaks following m vitro incubation or m vtvo rejection, suggesting conversion of ['~H]dynorphm A to smaller opmte actwe forms is not a major pathway of degradation In contrast, we d~d observe a small but consistent peak of radioactiwty that co-migrates on HPLC w~th Leu-enkephalin and co-elutes with the tyrosine on G-10 siewng column. Without another system for ~dent~fication such as thin layer chromatography for amino acid sequence we are unable to conclude that this radioactive material is Leu-enkephahn, however, authentic Leu-enkephahn would be so rapidly degraded under these c~rcumstances that we would not expect to see Leu-enkephahn [9, 33, 34] . Since we are unable to demonstrate ['~H]Tyr-Gly-Gly formation that would be generated by the breakdown of [3H]Leu-enkephalin, the generation of Leu-enkephalin would appear to be a relatively minor pathway tf at occurs at all.
Although the ammopepttdase cleavage of tyrosme could be accomplished by a general aminopeptidase, the mhibthon of this action by dT dynorphm and dynorphm A 7-17, suggests there may be a specific enzyme that cleaves dynorphin A with a recognition site m the COOH-termlnal domain of dynorphin A. The inhibition of this amino peptidase actwtty by a compound which cannot function as a substrate (dynorphin A 7-17) supports a specific enzyme hypothesis Similar findings have been reported for dynorphin A 6-13, ~.e., that dynorphin A 6-13 blocks the breakdown of [lZSI]dynorphin A 1-13. Since we were able to demonstrate only a slight inhibition of the breakdown of [3H]dynorphin A by dynorphin A l-13, it is unclear if this enzyme is the same enzyme described by Leslie and Goldstein [20] . However, this may be due to rapid breakdown including carboxy terminal cleavage of dynorphin A 1-13. Obviously, further studies are necessary to confirm the existence of such an enzyme, but possible mhlbitors of this enzyme could prowde other avenues of approach to studying the tn vlvo pharmacological effects of dynorphln A.
We have included data from guinea pig brain, even though prehmmary, to point out there may be species differences m the stability of dynorphin A under binding conditions across species. In wew of the slower breakdown of dynorphin A m vto o, it may be of interest to pursue a comparison of dynorphln A and dynorphin A 2-17 effects in vtvo m guinea pigs.
In conclusion, m rat, it appears that dynorphin A is rapidly broken down to dynorphm A 2-17, a non-opioid but behaworally active fragment of dynorphm. The rapidity of this breakdown m wvo may explain the difficulty in demonstratmg oplold effects of dynorphin A m v~vo in th~s species. The large number of non-op~otd effects observed following m vtvo rejection of dynorphin A, which can be mimicked by dynorphm A 2-17, may occur through the conversion of dynorphm A to the behaviorally active dynorphm A 2-17 fragment
